Infect Dis:一项关于自然恶性疟原虫种群对青蒿素和配对药物抗药性分子标记的横断面研究

2018-05-30 MedSci MedSci原创

<p class="MsoNormal" style="margin-bottom:0cm;margin-bottom:.0001pt;text-align: justify;text-justify:inter-ideograph;line-height:normal;mso-layout-grid-align: none;text-autospace:none">抗药性是疟疾控制面临的最大

抗药性是疟疾控制面临的最大挑战之一,监测疟原虫对青蒿素或对青蒿素联合疗法(ACT)的配对药物的抗药性对疟疾消除至关重要。本研究对喀麦隆西南部的自然疟原虫种群的一系列抗疟药物抗性标记进行了评估。

20135月到20143月,在喀麦隆山的侧面区域,将无症状的疟原虫血症或非重症疟疾的患者纳入本项横断面调查。利用光学显微镜从血液样本中筛选出含有恶性疟原虫的血液,去除白细胞后用CF11纤维素柱和HiSeq平台对疟原虫基因型进行了测序。

共有来自3个不同海拔地区的259名参与者纳入了本项研究。在pfdhfrpfmdr1pfcrt中与抗药性相关的一些等位基因非常普遍,所有样本中仅有不到3%的携带pfkelch13基因突变,其中没有一种与东南亚青蒿素疟原虫清除率降低相关。最常见的pfcrtpfmdr1pfdhfrpfdhps单倍体分别为pfcr-47576的三突变体,即C72V73I74E75T76(47.3%),在184位密码子的单碱基突变、N86F184D1246(53.2%)I51R59N108I164(99%)S436G437K5突变。

pfcrt CVIETdhfr IRN三种突变疟原虫的优势以及pfkelch13抗性等位基因的缺失表明在喀麦隆西南部阿莫地喹和 AS-AQSP组合的乙胺嘧啶疗法可能不再有效,而氯喹抗药性仍然存在。

Tobias O Apinjoh, Regina N Mugri,, et. al. Molecular markers for artemisinin and partner drug resistance in natural Plasmodium falciparum populations following increased insecticide treated net coverage along the slope of mount Cameroon: Cross-sectional study

本文系梅斯医学MedSci原创编译整理,转载需授权!


评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2012690, encodeId=5e5c2012690a3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 27 08:20:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041562, encodeId=e5eb204156293, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 20 09:20:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387858, encodeId=fddc138e858ab, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495384, encodeId=4fea1495384ba, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578832, encodeId=8cc815e883294, content=<a href='/topic/show?id=9b395292257' target=_blank style='color:#2F92EE;'>#恶性疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52922, encryptionId=9b395292257, topicName=恶性疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5f16444736, createdName=ms6832696159214430, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320034, encodeId=4f5a3200340b, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed May 30 18:51:12 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2012690, encodeId=5e5c2012690a3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 27 08:20:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041562, encodeId=e5eb204156293, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 20 09:20:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387858, encodeId=fddc138e858ab, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495384, encodeId=4fea1495384ba, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578832, encodeId=8cc815e883294, content=<a href='/topic/show?id=9b395292257' target=_blank style='color:#2F92EE;'>#恶性疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52922, encryptionId=9b395292257, topicName=恶性疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5f16444736, createdName=ms6832696159214430, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320034, encodeId=4f5a3200340b, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed May 30 18:51:12 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2012690, encodeId=5e5c2012690a3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 27 08:20:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041562, encodeId=e5eb204156293, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 20 09:20:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387858, encodeId=fddc138e858ab, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495384, encodeId=4fea1495384ba, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578832, encodeId=8cc815e883294, content=<a href='/topic/show?id=9b395292257' target=_blank style='color:#2F92EE;'>#恶性疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52922, encryptionId=9b395292257, topicName=恶性疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5f16444736, createdName=ms6832696159214430, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320034, encodeId=4f5a3200340b, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed May 30 18:51:12 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2012690, encodeId=5e5c2012690a3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 27 08:20:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041562, encodeId=e5eb204156293, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 20 09:20:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387858, encodeId=fddc138e858ab, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495384, encodeId=4fea1495384ba, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578832, encodeId=8cc815e883294, content=<a href='/topic/show?id=9b395292257' target=_blank style='color:#2F92EE;'>#恶性疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52922, encryptionId=9b395292257, topicName=恶性疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5f16444736, createdName=ms6832696159214430, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320034, encodeId=4f5a3200340b, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed May 30 18:51:12 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
    2018-06-01 songbq
  5. [GetPortalCommentsPageByObjectIdResponse(id=2012690, encodeId=5e5c2012690a3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 27 08:20:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041562, encodeId=e5eb204156293, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 20 09:20:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387858, encodeId=fddc138e858ab, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495384, encodeId=4fea1495384ba, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578832, encodeId=8cc815e883294, content=<a href='/topic/show?id=9b395292257' target=_blank style='color:#2F92EE;'>#恶性疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52922, encryptionId=9b395292257, topicName=恶性疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5f16444736, createdName=ms6832696159214430, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320034, encodeId=4f5a3200340b, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed May 30 18:51:12 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2012690, encodeId=5e5c2012690a3, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sat Oct 27 08:20:00 CST 2018, time=2018-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041562, encodeId=e5eb204156293, content=<a href='/topic/show?id=a8de6299654' target=_blank style='color:#2F92EE;'>#横断面#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62996, encryptionId=a8de6299654, topicName=横断面)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Feb 20 09:20:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387858, encodeId=fddc138e858ab, content=<a href='/topic/show?id=25ffe04313d' target=_blank style='color:#2F92EE;'>#疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70431, encryptionId=25ffe04313d, topicName=疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7e622500011, createdName=12498484m46(暂无昵称), createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1495384, encodeId=4fea1495384ba, content=<a href='/topic/show?id=cdd8556826f' target=_blank style='color:#2F92EE;'>#抗药性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55682, encryptionId=cdd8556826f, topicName=抗药性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=110a9169530, createdName=songbq, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578832, encodeId=8cc815e883294, content=<a href='/topic/show?id=9b395292257' target=_blank style='color:#2F92EE;'>#恶性疟原虫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52922, encryptionId=9b395292257, topicName=恶性疟原虫)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b5f16444736, createdName=ms6832696159214430, createdTime=Fri Jun 01 08:20:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320034, encodeId=4f5a3200340b, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed May 30 18:51:12 CST 2018, time=2018-05-30, status=1, ipAttribution=)]
    2018-05-30 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

J Antimicrob Chemother:全科医师在线培训能降低呼吸道感染儿童抗菌药物处方

近年来,抗菌药物的使用率非常高,而抗菌药物滥用会给患者尤其是儿童患者带来种种风险。2018年2月,发表在《J Antimicrob Chemother.》的一项实用的群组随机对照试验调查了初级医疗中全科医师在线培训和针对家长的信息小册子对呼吸道感染(RTI)儿童抗菌药处方的影响。

Emerg Microbes Infect.:我国科学家报道中国首例“超级真菌”感染病例——并非所有耳念珠菌都是“超级真菌

真菌感染是我国和全世界范围内临床医学中面临的重要威胁。耳念珠菌(Candida auris)是2009年日本发现的一种新病原真菌物种。因为该菌具有多重耐药和致死率高的特征,也被称为“超级真菌”。近年来,耳念珠菌在全世界不同国家快速传播,并导致严重的医院内感染。到目前为止,在全球5大洲至少20个国家已有临床感染病例的报道,其中包括中国、日本、美国、加拿大、英国、法国、西班牙、印度、巴基斯坦、韩国、南

GUT:内镜检查后感染风险研究

研究发现,内镜检查后感染的发生率较高,高于之前的预计,不同机构差异显著

PNAS:体温越高,越能更好地对抗癌症和感染

近日,来自英国沃里克大学和曼彻斯特大学的最新研究发现,体温越高,人体对抗肿瘤、伤口或感染的关键防御系统加速就越快。

Macromol Rapid Commun:同时具备抗菌成骨功能的复合微球可有效用于感染骨缺损的修复

骨缺损修复,尤其是感染方面,仍然是临床治疗中的一大挑战。为满足临床需要,同时具备抗菌活性和强大的骨生成效应的支架材料是骨组织工程中的一种有前景的方法。 在本研究中,研究人员制备了一种生物可吸收多孔结构微球体,由聚(I-丙交酯)和聚(乙二醇)嵌段组成的两亲嵌段共聚物制成。表面涂覆贻贝来源聚多巴胺后,通过依次生物矿化还原硝酸银和磷灰石,使微球载有纳米银。 将所制备的复合微球与大鼠骨间充质基

Front Pharmacol:SR-PM-Ag-HA可用于感染区骨缺损的修复

长骨开放骨折的骨感染率为4-64%,关节手术的骨感染率为近1%。治疗骨感染和感染相关的骨丧失非常重要。本研究通过一种新型油包水纳米悬浮液(S/O/N)方法组装银纳米颗粒(AgNPs)和羟基磷灰石纳米颗粒(HANPs)(SR-PM-Ag-HA)制备了雷奈酸锶(SR)负载的聚乳酸-乙醇酸共聚物(PLGA)微球,以实现骨诱导性和抗菌性能。 研究人员评估了微观结构、药物释放、生物相容性、骨诱导性和体